Alignment Healthcare CMO sells 18,600 shares; 10b5-1 plan adopted Mar 14

Q: What did ALHC insider Hyong (Ken) Kim report on Form 4?

The Form 4 reports the sale of 18,600 shares of Alignment Healthcare common stock on 08/13/2025 and shows 472,167 shares beneficially owned after the sale.

Q: What price did ALHC shares sell for in this reported transaction?

The filing reports a weighted-average price of $15.0327 per share and discloses individual trade prices ranged from $15.00 to $15.09 .

Q: Who signed the Form 4 for the reporting person?

The Form 4 was signed by Christopher J. Joyce, as Attorney-in-Fact , on behalf of Hyong (Ken) Kim on 08/15/2025 .

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alignment Healthcare Chief Medical Officer Hyong (Ken) Kim reported the sale of 18,600 shares of the company’s common stock on 08/13/2025 under a Rule 10b5-1 trading plan adopted on 03/14/2025. The sales generated a weighted-average price of $15.0327 per share, with individual trades executed between $15.00 and $15.09. After the reported transactions, the reporting person beneficially owned 472,167 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses the plan adoption date and the price range for the multiple sales.

Positive

Transaction executed under a Rule 10b5-1 plan adopted 03/14/2025, indicating pre-authorized trades
Disclosure of weighted-average price and per-share price range ($15.00 to $15.09) with an offer to provide detailed breakdown on request

Negative

Disposition of 18,600 shares on 08/13/2025 reduced the reporting person’s holdings
Beneficial ownership decreased to 472,167 shares following the reported sale

Insights

TL;DR: Insider sold a small portion of holdings under a pre-established 10b5-1 plan; disclosure is routine and non-material on its face.

The Form 4 shows a planned disposition of 18,600 shares executed on 08/13/2025 under a Rule 10b5-1 plan adopted 03/14/2025. The use of a 10b5-1 plan indicates trades were pre-authorized; the filing reports a weighted-average sale price of $15.0327 and a disclosed per-share price range of $15.00 to $15.09. Post-transaction beneficial ownership stands at 472,167 shares. For most investors this is a routine insider liquidity event rather than a corporate-change signal.

TL;DR: Disclosure meets Section 16 requirements and documents a Rule 10b5-1 plan sale with transparent price-range reporting.

The filing clearly identifies the reporting person’s role as Chief Medical Officer and confirms the transaction was executed pursuant to a 10b5-1 plan adopted 03/14/2025. The reporting includes a weighted-average sale price and a commitment to provide transaction-level pricing if requested, which enhances transparency. The filing is signed by an attorney-in-fact, consistent with permitted representation on Form 4 submissions.

Insider Trade Summary

Net Seller: 18,600 shares ($279,608)

Net Sell 1 txn

Insider Kim Hyong

Role Chief Medical Officer

Sold 18,600 shs ($280K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,600	$15.0327	$280K

Holdings After Transaction: Common Stock — 472,167 shares (Direct)

Footnotes (1)

Date of Rule 10b5-1 plan adoption: 03/14/2025 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.00 to $15.09. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Form 4 Insider Transactions: What Each Field Means →

08/15/2025 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Hyong

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE

92868

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/13/2025		S⁽¹⁾		18,600	D	$15.0327⁽²⁾	472,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/14/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.00 to $15.09. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for Hyong (Ken) Kim	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ALHC insider Hyong (Ken) Kim report on Form 4?

The Form 4 reports the sale of 18,600 shares of Alignment Healthcare common stock on 08/13/2025 and shows 472,167 shares beneficially owned after the sale.

Were the sales part of a pre-approved trading plan for ALHC insider transactions?

Yes. The Form 4 states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 03/14/2025.

What price did ALHC shares sell for in this reported transaction?

The filing reports a weighted-average price of $15.0327 per share and discloses individual trade prices ranged from $15.00 to $15.09.

Who signed the Form 4 for the reporting person?

The Form 4 was signed by Christopher J. Joyce, as Attorney-in-Fact, on behalf of Hyong (Ken) Kim on 08/15/2025.

Does the Form 4 provide a breakdown of the number of shares sold at each price?

No specific per-trade breakdown is provided in the filing; the reporting person offers to provide full information on request regarding the number of shares sold at each price within the disclosed range.